NPPB and pulmonary arterial hypertension: Using the same cohort of patients with PAH, Simpson et al further investigated the prognostic potential of soluble suppression of tumorigenicity 2 (ST2) and galectin 3—recently FDA-approved biomarkers in noninvasive risk stratification of left heart failure—along with NT-proBNP.78